Omega-3 fatty acids, pro-inflammatory signaling and neuroprotection

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 10, Issue 2, 2007, Pages 136-141

  Bazan, Nicolas G ^a  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Alzheimer's disease; Neuroprotectin D1; Retinal pigment epithelium; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN[1-40]; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; NEUROPROTECTIN D1; NEUROPROTECTIVE AGENT; OMEGA 3 FATTY ACID; PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRAIN ISCHEMIA; BRAIN PERFUSION; CELL CULTURE; CEREBROVASCULAR ACCIDENT; CONTINUOUS INFUSION; DRUG ACTIVITY; HUMAN; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PIGMENT EPITHELIUM; PROTEIN EXPRESSION; REVIEW;

BRAIN; DOCOSAHEXAENOIC ACIDS; HUMANS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; REPERFUSION INJURY; RETINA; SIGNAL TRANSDUCTION;

EID: 33846857139     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e32802b7030     Document Type: Review

References (56)

1. Birkle DL, Bazan NG. Effect of bicuculline-induced status epilepticus on prostaglandins and hydroxyeicosatetraenoic acids in rat brain subcellular fractions. J Neurochem 1987; 48:1768-1778.
2. Aveldano MI, Bazan NG. Differential lipid deacylation during brain ischemia in a homeotherm and a poikilotherm: content and composition of free fatty acids and triacylglycerols. Brain Res 1975; 100:99-110.
3. Scott BL, Bazan NG. Membrane docosahexaenoate is supplied to the developing brain and retina by the liver. Proc Natl Acad Sci U S A 1989; 86:2903-2907.
4. Gamoh S, Hashimoto M, Sugioka K, et al. Chronic administration of docosahexaenoic acid improves reference memory-related learning ability in young rats. Neuroscience 1999; 93:237-241.
5. McGahon BM, Martin DS, Horrobin DF, et al. Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. Neuroscience 1999; 94:305-314.
6. Gordon WC, Bazan NG. Docosahexaenoic acid utilization during rod photo-receptor cell renewal. J Neurosci 1990; 10:2190-2202.
7. Mirnikjoo B, Brown SE, Kim HF, et al. Protein kinase inhibition by omega-3 fatty acids. J Biol Chem 2001; 276:10888-10896.
8. Lauritzen I, Blondeau N, Heurteaux C, et al. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 2000; 19:1784-1793.
9. Rodriguez de Turco EB, Belayev L, Liu Y, et al. Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin. J Neurochem 2002; 83:515-524.
10. Bazan NG, Birkle DL, Reddy TS. Docosahexaenoic acid (22:6, n-3) is metabolized to lipoxygenase reaction products in the retina. Biochem Biophys Res Commun 1984; 125:741-747.
11. Royo NC, Wahl F, Stutzmann JM. Kinetics of polymorphonuclear neutrophil infiltration after a traumatic brain injury in rat. Neuroreport 1999; 10:1363-1367.
12. Chopp M, Li Y, Zhang RL, et al. Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. J Cereb Blood Flow Metab 1996; 16:578-584.
13. Mabuchi T, Kitagawa K, Ohtsuki T, et al. Contribution of microglia/macrophages to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. Stroke 2000; 31:1735-1743.
14. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003; 278:43807-43817.
15. Serhan CN, Clish CB, Brannon J, et al. Novel functional sets of lipid-derived mediators with anti-inflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal anti-inflammatory drugs and transcellular processing. J Exp Med 2000; 192:1197-1204.
16. Serhan CN, Hong S, Gronert K, et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med 2002; 196:1025-1037.
17. Nourooz-Zadeh J, Liu EH, Yhlen B, et al. F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer's disease. J Neurochem 1999; 72:734-740.
18. Lukiw WJ, Bazan NG. Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J Neurosci Res 1998; 53:583-592.
19. Bazan NG, Lukiw WJ. Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells. J Biol Chem 2002; 277:30359-30367.
20. Xu J, Chen S, Ahmed SH, et al. Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci 2001; 21:RC118.
21. Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress [review]. Brain Pathol 2005; 15:159-166.
22. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease [review]. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:741-749.
23. Prasad MR, Lovell MA, Yatin M, et al. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem Res 1998; 23:81-88.
24. Montine TJ, Neely MD, Quinn JF, et al. Lipid peroxidation in aging brain and Alzheimer's disease. Free Radic Biol Med 2002; 33:620-626.
25. Suzuki H, Park SJ, Tamura M, et al. Effect of the long-term feeding of dietary lipids on the learning ability, fatty acid composition of brain stem phospholipids and synaptic membrane fluidity in adult mice: a comparison of sardine oil diet with palm oil diet. Mech Ageing Dev 1998; 101:119-128.
26. Kyle DJ, Schaefer E, Patton G, et al. Low serum docosahexaenoic acid is a significant risk factor for Alzheimer's dementia. Lipids 1999; 34 (Suppl):S245.
27. Gamoh S, Hashimoto M, Hossain S, et al. Chronic administration of docosahexaenoic acid improves the performance of radial arm maze task in aged rats. Clin Exp Pharmacol Physiol 2001; 28:266-270.
28. Ikemoto A, Ohishi M, Sato Y, et al. Reversibility of n-3 fatty acid deficiency-induced alterations of learning behavior in the rat: level of n-6 fatty acids as another critical factor. J Lipid Res 2001; 42:1655-1663.
29. Catalan J, Moriguchi T, Slotnick B, et al. Cognitive deficits in docosahexaenoic acid-deficient rats. Behav Neurosci 2002; 116:1022-1031.
30. Kalmijn S, Launer LJ, Ott A, et al. Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 1997; 42:776-782.
31. Barberger-Gateau P, Letenneur L, Deschamps V, et al. Fish, meat, and risk of dementia: cohort study. BMJ 2002; 325:932-933.
32. Grant WB, Campbell A, Itzhaki RF, et al. The significance of environmental factors in the etiology of Alzheimer's disease. J Alzheimers Dis 2002; 4:179-189.
33. Yamada T, Kadekaru H, Matsumoto S, et al. Prevalence of dementia in the older Japanese-Brazilian population. Psychiatry Clin Neurosci 2002; 56:71-75.
34. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60:940-946.
35. Lim GP, Calon F, Morihara T, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005; 25:3032-3040. Demonstration that diets enriched in DHA attenuate amyloid deposition in a neurodegeneration mouse model.
36. Guo Q, Robinson N, Mattson MP. Secreted beta-amyloid precursor protein counteracts the proapoptotic action of mutant presenilin-1 by activation of NFkappaB and stabilization of calcium homeostasis. J Biol Chem 1998; 273:12341-12351.
37. Selkoe D, Kopan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu Rev Neurosci 2003; 26:565-597.
38. Kaur J, Dhaunsi GS, Turner RB. Interleukin-1 and nitric oxide increase NADPH oxidase activity in human coronary artery smooth muscle cells. Med Princ Pract 2004; 13:26-29.
39. Zhang Y, McLaughlin R, Goodyer C, et al. Selective cytotoxicity of intracellular amyloid beta peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol 2002; 156:519-529.
40. Colangelo V, Schurr J, Ball MJ, et al. Gene expression profiling of 12 633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002; 70:462-473.
41. Liao YF, Wang BJ, Cheng HT, et al. Tumor necrosis factor-alpha, interleukin-1beta, and interferon-gamma stimulate gamma-secretase-mediated cleavage of amyloid precursor protein through a JNK-dependent MAPK pathway. J Biol Chem 2004; 279:49523-49532.
42. Akhtar RS, Ness JM, Roth KA. Bcl-2 family regulation of neuronal development and neurodegeneration. Biochim Biophys Acta 2004; 1644:189-203.
43. Lukiw WJ, Cui JG, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115:2774-2783. Demonstration of NPD1 in human brain. Finding that NPD1 content is decreased in CA1 area of hippocampus. In human brain cells in culture, this study demonstrates that NPD1 induces a antiapoptotic, anti-inflammatory cell survival program by modifying gene expression.
44. Metcalfe AD, Hunter HR, Bloor DJ, et al. Expression of 11 members of the BCL-2 family of apoptosis regulatory molecules during human preimplantation embryo development and fragmentation. Mol Reprod Dev 2004; 68:35-50.
45. Tarte K, Jourdan M, Veyrune JL, et al. The Bcl-2 family member Bfl-1/A1 is strongly repressed in normal and malignant plasma cells but is a potent antiapoptotic factor for myeloma cells. Br J Haematol 2004; 125:373-382.
46. Bahr BA, Hoffman KB, Yang AJ, et al. Amyloid beta protein is internalized selectively by hippocampal field CA1 and causes neurons to accumulate amyloidogenic carboxyterminal fragments of the amyloid precursor protein. J Comp Neurol 1998; 397:139-147.
47. Kim HJ, Chae SC, Lee DK, et al. Selective neuronal degeneration induced by soluble oligomeric amyloid beta protein. FASEB J 2003; 17:118-120.
48. Pelvig DP, Pakkenberg H, Regeur L, et al. Neocortical glial cell numbers in Alzheimer's disease: a stereological study. Dement Geriatr Cogn Disord 2003; 16:212-219.
49. Kobayashi K, Hayashi M, Nakano H, et al. Correlation between astrocyte apoptosis and Alzheimer changes in gray matter lesions in Alzheimer's disease. J Alzheimers Dis 2004; 6:623-632.
50. Paradisi S, Sacchetti B, Balduzzi M, et al. Astrocyte modulation of in vitro beta-amyloid neurotoxicity. Glia 2004; 46:252-260.
51. Kitamura Y, Taniguchi T, Shimohama S. Apoptotic cell death in neurons and glial cells: implications for Alzheimer's disease. Jpn J Pharmacol 1999; 79:1-5.
52. Calon F, Lim GP, Yang F, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004; 43:633-645.
53. Hashimoto M, Tanabe Y, Fujii Y, et al. Chronic administration of docosahexaenoic acid ameliorates the impairment of spatial cognition learning ability in amyloid (beta)-infused rats. J Nutr 2005; 135:549-555.
54. Mukherjee PK, Marcheselli VL, Serhan CN, et al. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A 2004; 101:8491-8496.
55. Hong HS, Hwang EM, Sim HJ, et al. Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. Biochem Biophys Res Commun 2003; 307:922-927.
56. Lahiri DK, Chen D, Vivien D, et al. Role of cytokines in the gene expression of amyloid beta-protein precursor: identification of a 5′-UTR-binding nuclear factor and its implications in Alzheimer's disease. J Alzheimers Dis 2003; 5:81-90.